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is decreased in pustular forms of psoriasis. 
A clue to the pathogenesis of pustule formation?
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Abstract Skin-derived antileukoproteinase (SKALP, Key words Proteinase inhibitor • 
also known as elafin) is an inducible epiderm al serine leukocyte 
proteinase inhibitor, that we have recently character-
ized at the protein and DNA levels. SKALP is a strong ----------------------------------------------------------------------------
and specific inhibitor of PMN elastase, and is putatively Introduction 
involved in the regulation of cutaneous inflammatory
processes. In o rder to investigate the role of SKALP in Several cutaneous manifestations of psoriasis are known
the control of elastase in psoriatic epidermis, we com- [1]. Erthematosquamous lesions can vary in size from
pared SKALP expression in norm al skin, and in skin pinpoint to large plaques or even erythroderma. Psoriatic
from patients with chronic plaque psoriasis and pustular lesions can also be present as pustules rather than the
forms of psoriasis. Epiderm al scales and biopsies were more usual plaques. These lesions may be localized (per-
collected and SKALP expression was studied at the sistent pustulosis palmoplantaris) or generalized (general-
mRNA level and at the protein level both functionally ized pustular psoriasis). The aetiology of psoriasis (or its
and immunochemically. In epiderm al scales, we found subforms) is unknown. Both a defect in growth control
that the levels of both free and  total SKALP activity in mechanisms of keratinocytes [2], i an underlying
pustular psoriasis were far lower than in plaque psoria- (auto)immune process have been implicated [3]. Recently, 
sis. A significant num ber of pustu lar psoriasis patients alterations in cytokine production and responsiveness to 
showed latent SKALP activity, which represents the cytokines have been described which may be causally re­
amount of SKALP putatively complexed to elastase. In luted to the disease process [4|.
addition, we found free elastase activity in 25% of the One of the main features of psoriatic lesions is the
pustular psoriasis patients, indicating a total saturation presence of 
of epidermal SKALP activity. In epidermal biopsies epidermis, e
:lear leukocytes (PMN) in the
scattered or in the form of micropustules 
from pustu lar psoriasis patients, SKALP activity was or microabcesses. In pustular forms of psoriasis an extreme
significantly decreased com pared with from local infiltration of PMN occurs. Although it is unlikely that
plaque psoriasis patients. N orthern blot analysis did PMN infiltration is a primary event related to the aetiology 
not reveal differences in epiderm al niRNA levels be- of the disease, the formation of spongiform pustules re-
94 IStween chronic plaque psoriasis and pustular psoriasis, suiting from
We hypothesize tha t a reduced am ount of epidermal cific process. Activated PMN induce tissue damage, and
SKALP contributes to an imbalance between elastase perpetuate the inflammatory response by the secretion of
and its inhibitor, thereby prom oting the formation of proteinases (e.g. elastase), reactive oxygen meti
pustules. We suggest that these findings and prostanoids. We have shown in previous studies that
could provide a rationale for the treatm ent of pustular most antipsoriatic agents interfere in vivo 
psoriasis with inhibitors of PM N-derived proteinases, B4-induced PMN infiltration in human skin, suggesting that 
as a new therapeutic modality. this might be one of the antipsoriatic mechanisms of cor­
ticosteroids, dithranol, retinoids and methotrexate [5]. 
Recently we have described a new, inducible, keratino-
in psoriatic
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but absent in normal skin [6-8
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PMN migration and tissue destruction in many conditions Préparation of the antisera
including lung emphysema [9], arthritis [10], glomeru- An antiserum against recombinant SKALP (a kind gift from Dr. N.
lonephritis [11] and bullous dermatoses [12, 13]. We have Russelu ICI Pharmaceuticals, UK) was obtained as described pre­
characterized SKALP, which is also known as elafin [14, viously [8], An antiserum against a synthetic peptide comprising 
15] or ESI [16], at the biochemical level [7], and have amino acid 23 to 36 of preSKALP (Eurosequence, Groningen, The
shown its presence in urine and serum of psoriatic patients Netherlands) was prepared. This peptide was coupled via a C-ter-
ti n in i  r' *.1 i i j  -4. • • minal cysteine residue to chicken ovalbumin (Sigma, St Louis,[17, 18], Furthermore, we have located its expression in M() ^  using the su|fo.SMCC procedure (Pierce, Rockford,
differentiated epidermal keratmocytes [8]. The SKALP m., USA). This preparation was used for immunization of a rabbit
cDNA and gene have been cloned [19, 20] and we have 
been able to assign the chromosomal localization of the 
SKALP gene to chromosome 20q [21 ]. The gene has been
given the approved name of protease inhibitor, skin de- Preparation of scale extracts
rived (SKALP), symbol PI3, in the Genome Data base of
the HUGO nomenclature committee. Scales were processed tor determination oi SKALP activity as de­
scribed previously [6]. In brief, scales were weighed and then ho-
according to previously described protocols [7]. Preimmune serum 
was drawn as a control.
clear supernatant was divided into two equal portions. One portion 
was boiled for 2 min to inactivate elastase and to liberate the elas-
Although the induction oi SKALP in inflammatoiy rnogenized (100 mg/ml) in a glass-glass grinder in a phosphate-
dermatoses (e.g. psoriasis) and its substrate specificity buffered saline (PBS) and centrifuged (15 min, 12 ..........  "
suggest that SKALP is involved in the regulation of cuta­
neous elastase activity, no data so far exist to support this . /WWA
nvKlimpH rn1„ Wp rM?nnP(1 nnr|pr rnnH tfinm  n f  pv- tase-bound inhibitor and then again centrifuged (15 min, 12 000 }>).
pi s i m  d ol . W  c c c co n d  ion . Colorimetric quantification of the protein concentration was per-
cessive elastase secretion, SKALP should be present in a formed using the Bio-Rad DC Protein Assay according to the
complexed form with elastase. In extreme cases, when all recommendations o f  the supplier (Bio-Rad Laboratories, Rich-
available SKALP is consumed, one would expect free mond, Calif., USA), 
elastase activity. We therefore investigated the amounts of
free and latent SKALP in scales and biopsies from pa- Protein and RNA extraction 
tients with chronic plaque psoriasis or pustular psoriasis.
To study  local differences in one in d iv id u a l, biopsies were From the keratome biopsies RNA and protein were simultaneously
tak-pn fm m  Ipcinn'il cVin w ith  nnctnlps and w ithnnt nn«- isolated usinS Tri Reagent (MRC, Cincinnati, Ohio, USA), ac-
O kin w  h p th p cording to the manufacturer’s guidelines. In brief, samples were
tules. Different methods were used for studying SKALP homogenized in 1 ml Tri Reagent and separated with chloroform
levels including functional measurement, immunochemi- in an aqueous phase, an interphase and a phenol-chloroform phase,
cal techniques, immunohistochemical staining and North- RNA was precipitated in the aqueous phase with 0.5 ml iso-
em blot analysis. We indeed found that in the majority of 3 } * £  *£ * S
the patients with pustular forms of psoriasis, SKALP was
ing dissolved in XNSE buffer (50 mM  NaAc, 0.2% SDS, 2 mM  
EDTA). Samples were stored after adding 100% ethanol at -8 0 °  C 
decreased at the protein level. The mechanism of pustule until further study. After precipitation of DNA with 100% ethanol,
formation, and the therapeutic implications of these find- proteins were precipitated from the phenol ethanol supernatant
with isopropanol. The protein pellet was washed three times in 0.3 
M guanidine hydrochloride in 95% ethanol and once with 100% 
ethanol. After vacuum drying, the protein pellet was dissolved in 
PBS and stored at 4°C . Colorimetric quantification of the protein 
concentration was performed using the Bio-Rad DC Protein Assay.
ings are discussed.
Materials and methods
Patients
Functional measurement of SKALP activity in scales and biopsies
Scales were collected from 16 patients with chronic plaque psoria­
sis and 19 patients with pustular psoriasis, either localized or gen- Because of the complex situation of both free elastase and elasta.se
eralized (acrodermatitis continua of Hallopeau n =  1; pustulosis complexed with inhibitor, we used a protocol previously described
palmoplantaris, n -  13; generalized pustular psoriasis von Zum- lor the measurement of anti-elastase activity in urine (17] based on
busch type, n — 2; nongeneralized pustular psoriasis, n — 3). All pa- l*lc differential heat stability of elastase and SKALP. Blast use is
tients had active disease. Keratome biopsies (thickness 0.4 mm, denatured by boiling the scale extract lor 2 min, whereas SKALP
area I cm2) for RNA and protein isolation were taken from six *-s stable. I he bound elastase inhibitor (latent SKALP) is re-
healthy individuals from the skin of the back and from clinically leased from the enzyme-inhibitor complex. In all scale extracts we
involved skin of six patients with plaque psoriasis. Two keratome measured the free SKALP activity in untreated samples and the to-
biopsies were taken from six patients with pustular psoriasis (aero- ta* (l^ent plus tree) SKALP activity in heat-inactivated samples.
dermatitis continua of Hallopeau, n — 1; pustulosis palmoplantaris, 1° protein solutions of biopsies only total SKALP activity could be
n = 3; erythroderma with pustule formation, n = 2), one from a skin measured because of the denaturing isolation procedure.
region with macroscopic pustules and one from a region without Serial dilutions were made from the samples in assay buffer
pustules. Punch biopsies (4 mm) for histology were taken from a (I M NaCI, 0.4% CTAB, 0.1 M Tris, pH 8.5). Elastase activity was 
patient with annular pustular psoriasis and from a patient with gen- measured as the release of the f luorogenic substrate mcthoxy-suc-
cinyl-alanyl-alanyl-prolyl-valyl-amino-4-methylcoumarin 
(MAAPV-AMC, Sigma, St. Louis, Mo., USA) as described previ­
ously [11). Fluorescence was measured at 375 nm (excitation) and 
440 nm (emission) in a Perkin-Elmer LS-5 fluorimeter.
SKALP activity was measured as the percentage inhibition of a
eralized pustular psoriasis. Before the biopsies were taken, permis­
sion of the medical ethical committee and written informed con­
sent from the patients were obtained. Prior to analysis, scales and 
keratome biopsies were stored at -2 0 °  C and -8 0 °  C, respectively. 
Punch biopsies were fixed in buffered 4% formalin for at least 24
h and processed for routine histology. Tissue was embedded in standard amount of elastase using the same assay. An extract of
paraffin and 5-pm sections were cut. 500 PMN in assay buffer (equivalent to approximately 1 ng HLE) 
to a total volume of 10 pi was mixed with 10 ul serial dilutions of
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scale extract and then incubated for 15 min at 3 7 ° C. Elastase sub­
strate solution (20 jiil, 250 \xM) was then added and the reaction
and incubated with antiserum against recombinant SKALP at a di­
lution of 1:100. Detection of SKALP with an antiserum raised 
was allowed to proceed for 15 min at 37° C. The incubation was against a synthetic peptide gave an essentially similar localization 
terminated by the addition of 1 ml stop buffer (100 niM Na-jCO,, pattern (not shown). After incubation with peroxidase-conjugated 
pH 10.5). Inhibition of elastase activity in this assay was calculated swine antirabbit Ig (Dako, Glostrup, Denmark), the sections were
as the percentage inhibition of the activity o f 500 PMN, within the 
linear range of the assay. Recombinant SKALP (a kind gift from 
Dr. N. Russell, ICI Pharmaceuticals, UK) was used to obtain a cal­
ibration curve from which the SKALP concentration in the scale 
extracts was read. After correction for protein concentration, Statistics 
SKALP activity was expressed as nanograms SKALP per mil-
ligram protein.
Enzyme-linked immunosorbent assay 
for measurement of SKALP levels
developed with animoethylcarbazole as the chromogenic substrate. 
Preimmune serum from the immunized rabbit was used as a control.
For statistical evaluation the Mann-Whitney test was used for un­
paired samples and the Wilcoxon Signed Ranks’ test for paired
SKALP concentrations were measured in scale and biopsy ex Results
tracts, using a competitive-type ELISA, as described previously
118]. Scale extracts were boiled and supernatants were taken for SKALP in scale extracts
quantification of SKALP. Biopsy isolates were measured directly.
b,*eJ’ i eJ®ll0n i1« 1PIlixtlueJ^as EreS c fd to ?on}f i! 8om" In all samples we measured the free SKALP activity inpie: 0.1 M  Tris, 0.1% Tween-20, 1% BSA, and rabbit antiserum , , * , , , , „ * _
against recombinant SKALP (1:9500 diluted, and incubated over- untreated samples and the total (latent plus hee) SKALP
*  a  l b  a  .  . a  m
night. Microtitre plates (96 flat bottom wells) were coated over­ in heat-inactivated samples using a functional as- 
night with 50 ng/ml recombinant SKALP in PBS. After washing of say. The values in the scales of patients with pustular pso-
the plate with PBS/0.05 % Tween-20, the microtitre plates were ria>sjs =  19) and patients with chronic plaque psoriasis
blocked, probed with the test samples, and developed for 60 min , , , A ,
with peroxidase-conjugated swine-antirabbit Ig using «-phenyl- ~  16) ate  presented in Fig. I. A renuukable hnding was
enediamine dihydrochloride (OPD) as chromogenic substrate for that SKALP activity was significantly lower in the pustu
15 min. Human recombinant SKALP in PBS with 0.1% BSA was lar psoriasis group than in the plaque psoriasis group {P <
used as a standard: a calibration curve was prepared using recom- 0.01, Mann-Whitney test). This was found both for total
binant SKALP ¡" the range of 2 .9 -36  ng/ml The SKALP concen- S K A L p  and for  free S K ALP. Heat inactivation of the
trations m scales or biopsy samples were read from this curve. All . .
ELISA steps were performed at 4° C, except development with scale extracts revealed latent SKALP activity m  a consid-
OPD which was done at room temperature. The results were read erable number of patients in the pustular psoriasis group,
with a Biorad ELISA reader, and evaluated using the Excel spread- while in the plaque psoriasis group no latent SKALP was
sheet program. Alter correction lor protein concentration, SKALP founcj> in contrast, SKALP activity was higher after direct 
activity was expressed m nanograms SKALP per milligram protein. °
Northern blot analysis
measurement of the scale extracts than after heat inactiva­
tion.
In some patients SKALP activity was undetectable; in 
these patients free elastase activity was measurable. In the 
pustular psoriasis group this was found in five patients out 
of 19 (elastase activity equivalent to 41 ± 29 x 103 PMN 
per mg scales), and in the plaque psoriasis group only one 
patient was found with a small amount of free elastase 
(6000 PMN per mg scales). Remarkably, in’BOth patients 
with generalized pustular psoriasis of the von Zumbusch 
type, free elastase activity was found. In all six patients 
with free elastase activity, latent SKALP activity could be 
recovered after heat inactivation of elastase (not shown).
SKALP levels as measured using the ELISA in the su­
pernatant boiled scale extracts were the same as those ob­
tained using the functional assay. The SKALP concentra­
tion was significantly lower in patients with pustular pso­
riasis than in those with plaque psoriasis (P < 0.01, Mann- 
Whitney test). The SKALP levels measured using the
M I v / u  V » Jl I I V  J-.'# V % r W I TWJ* ft ■ v i n v »  v / i n  j f  t i * 4  » i *» f I * 1
lowing standard procedures. Autoradiography was done using an ELISA were within the same range as those round with 
X-Omat S film (Kodak, France) at - 80°C  with an intensifying the functional assay, indicating that the anti-elastase activ-
For Northern blot analysis, 10 fig o f total RNA was elec- 
trophoresed on a 1.4% agarose gel following standard procedures 
[221. In brief, 10 (.ig total RNA was dissolved in 3 |J.l RNAse-frce
water (prepared using a Milli-Q ultrafiltration apparatus, Milli- 
pore), and then 2 (.tl 0.1 M sodium phosphate (pH 7.0), 10 |il di­
methyl sulphoxide (DMSQ) and 4.5 j_i 1 6 M glyoxal was added. The 
mixture was incubated for 60 min at 50° C. After cooling the RNA 
samples to 0°C, 3.5 |il glyoxal /DM SO gel-loading buffer was 
added and the mixture immediately loaded into the wells of the 
gel. The gel was poured and run in 10 \\\M sodium phosphate. The 
buffer was recirculated to maintain the pH within acceptable lim­
its. The gel was then blotted by capillary transfer onto a nylon
■*r transfer,
RNA was fixed to the membrane by ultraviolet irradiation (312 
nm, 0.2 J/enr). Hybridization was performed as previously de­
scribed, using a 0.42 kbp Pvull/IuoRX fragment o f  the SKALP 
cDNA clone pGESKA as a probe 119|. Control hybridizations for 
equal loading were performed using a human 28S robosomal RNA 
probe. The probe was labelled with '-P by ra dom pr m ng, fol
membrane (Boehringer, Mannheim, Germany). Afte
screen. ity found was indeed largely due to SKALP.
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Fig. 1 SKALP concentration in scale extracts from patients with decreased in
chronic plaque psoriasis (n = 16) and pustular psoriasis (« = 19). p iaque psoriasis (P < 0 .0 1 ,  Mann-Whitney test). The
SKALP was determined using a functional assay after heat inacti- H J S A  sh ow e[, lo w e r  S K A L P  le v e l s  in both , he pustular  
vation, i.e. boiling lor 2 nun to inactivate elastase and to liberate , , . . , . . 1
the elastase-bound inhibitor, {filled bars) and directly (hatched region and the involved skin without pustules o( pustular
bars). The open bars represent SKALP concentration as measured psoriasis patients than in plaque psoriasis patients, but the
using an ELISA. SKALP levels were significantly lower in the difference did not reach significance, 
pustular psoriasis group than in the plaque psoriasis group. This
was found with functional measurements as well as with ELISA (P 
< 0.01, Mann-Whitney test). Heat inactivation resulted in a signif­
icant increase in SKALP concentration in the pustular psoriasis pa- Northern blot analysis
tients (P < 0.03, Wilcoxon Signed Ranks’ test for paired samples). 
Bars means ± SE Figure 3 shows the expression of SKALP rnRNA in the 
biopsies from normal skin, lesional skin from chronic 
riasis. In six patients with pustular psoriasis one biopsy plaque psoriasis patients and lesional skin horn pustular 
was taken from a region with pustules and one from an in- Ps01*fsis I n ^113 Psor},dtlc s ’m a sl_I0nS ex_ 
volved region without pustules to check for local differ- Pief>sion ol SKALP mRNA was ound (lanes . and 4), 
ences in the same individual. These biopsies were wheieas the noimal skin showec no expiession (lanes 1 
processed for simultaneous extraction of both the protein anc  ^ | n Pai,ec  ^ biopsies 11om tinee patients with pustu 
and RNA. The denaturing isolation procedure led to the Psori,as‘s ^ anes - a .n c , T  ’ 7 and 8, ) and 10, lespec- 
measurement of total SKALP in all protein fractions, tjvely) similai levels ol SKALI mRNA expiession weie 
SKALP activity as obtained from functional measure- lound as in psonatic skin. The expiession in pustulai ic- 
ments of anti-elastase activity is shown in Fig. 2. In normal &*ons ^ anes  ^ anc* ^  1101 1^0111 ^ie a,eas w*^“ 
skin no SKALP activity was found, whereas in psoriatic out macroscopic pustules (lanes 6, 8 and 10). 
skin high levels were found. SKALP activity in biopsies 
from the pustular region of pustular psoriasis patients was
Fig. 2 SKALP concentration in 
epidermal biopsies from healthy 
controls (n = 6), patients with 
chronic plaque psoriasis (n = 6) 
and patients with pustular psori­
asis (// ss 6). From the last group, 
two biopsies per patient were 
taken: one from a region with 
macroscopic pustules (pustular 
+) and one from a region with­
out pustules (pustular - ) .  SKALP 
was measured using a functional 
assay (filled bars) and an ELISA 
{open bars). SKALP activity as 
measured using the functional 
assay was significantly lower in 
the pustular + biopsies than in 
plaque psoriasis biopsies (P < 
0.01 ,  Mann-Whitney test). Bars 
means ± SE
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Fig. 3 Northern blot o f  SKALP m RNA in skin biopsies o f patients 
with chronic plaque psoriasis and pustular psoriasis (lower panel). 
In normal skin no expression o f  SKALP could be demonstrated
1 and 2), whereas skin from plaque psoriasis patients 
showed strong expression (lanes 3 and 4). Paired biopsies in three 
patients with pustular psoriasis from regions with macroscopic 
pustules and without pustules are shown (lanes 5 and 6, 7 and 8, 9 
and 10, respectively). Compared with
SKALP mRNA is equally expressed in both regions. The upper
We have previously reported that normal human skin and 
nonlesional psoriatic skin are negative for SKALP. Le- 
sional skin of chronic plaque psoriasis shows cytoplasmic 
staining of the upper layers of the suprabasal compart­
ment [8]. Here we performed immunohistochemical stain­
ing for SKALP in lesions of pustular psoriasis patients 
and compared the expression patterns with those obtained 
from psoriasis lesions. The SKALP expression pattern 
was similar in pustular and plaque psoriasis, i.e. basal 
cells were negative and there was positive staining in the 
upper suprabasal layers. In the epidermis near pustules, 
SKALP expression was clearly, but variably, affected by
panel shows control hybridizations using a human 28S ribosomal the Presence of lar8e amounts of PMN. Figure 4 shows
that several layers of SKALP-positive cells were presentRNA probe to check for equal RNA loading
Ilf . / J
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: l v :! ilrV: ^ I --;: ; - : V : - - - ' ; :-V VV: Vj -, : r j  :' : ; : -:iT ' i¿ : >: * i ’ : : r ;
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in the intact epidermis underlying a subcorneal pustule. 
No damage to the epidermis was evident. Figure 4b shows 
a pustule where the upper layers of the epidermis were de­
stroyed; here, only a few SKALP-positive cells were pre­
sent with low levels of expression.
Discussion
b
w.V.r.-
vV.: r:: : ^  ;■ : ■ ■■ r  s : : : : ' : : r : :
: V , ; . V i ^ i - . x ,: v : ; '
One of the putative functions of PMN elastase is to facil­
itate migration through connective tissue and basal mem­
branes, towards inflammatory foci. Speculatively, SKALP 
could counteract this process since it is synthesized in the 
upper epidermis and provides a gradient of anti-elastase 
activity from epidermis to dermis. In support of this con­
cept, we and others have indeed recently shown that 
SKALP can be found in the urine [17, 23] and serum [18] 
or psoriatic patients. In our view, the induction of SKALP 
in human epidermis is a negative feedback on cutaneous 
inflammation, to control PMN migration and protect
M íW:í#K-
tase inhibitors can be present simultaneously, either free 
orcomplexed: alpha-1-antitrypsin (alpha-1-AT), secretory 
leukocyte protease inhibitor (SLPI) and SKALP. From 
previous studies we know that SLPI activity in scales is 
low compared to SKALP, and disturbance by alpha-1-AT
in the assay by the presence of 
cetyltrimethylammonium bromide (CTAB). We therefore 
assume that most anti-elastase activity measured in our as­
say represents SKALP activity. Furthermore, we are deal­
ing in the epidermis with a complex situation. In psoriatic
in-
activity is
, Expression of SKALP in (a) a pustular area of psoriatic hibitoi was found, and dnect quantification o f  the total
skin, with an increased number o f  SKALP-positive cells present in amount ot biologically active SKALP was not possible, 
the intact epidermis underlying a subcorneal pustule, and (b) a Therefore, we used a protocol, previously described for
the measurement of anti-elastase activity in urine [17],o i« om*area
tule. Bars 100 um
of the epidermis {arrow). Note the absence o f  SKALP-positive , . , . , . , differential heat stabiHtv 0 f  elastase  
cells in the epidermal keratinocvtes underlying the subcorneal pus- ”  1 ‘ 4 k *■ ^
and SKALP.
In this study we examined the amounts of SKALP in 
scales and biopsies of psoriatic patients, either of the 
plaque type of pustular type of psoriasis. Most striking
646
total SKALP were considerably lower in pustular psoria- These findings make it less likely that the observed low 
sis than in plaque psoriasis; this was highly significant in SKALP levels have a genetic basis, although this possi- 
all subtypes of pustular psoriasis, despite the large varia- bility cannot be totally dismissed.
tion in levels of SKALP in each group. Furthermore, an The role of SKALP in the mechanism of pustule for-
unexpected finding was that SKALP activity after boiling mation is unclear. Speculatively, SKALP consumption
of the scale extracts was lower than after direct measure- could lead to local SKALP deficiencies which allow the
ment. We have previously studied [17] the effect of boil- formation of pustules of Kogoj or microabscesses of
ing on elastase activity. Boiling for 1—2 min gives an op- Munro as seen in psoriasis vulgaris. In extreme cases,
timal recovery of anti-elastase activity. Prolonged boiling macroscopic pustules arise as seen in pustular forms of
causes dénaturation of SKALP. This could be a fraction of psoriasis. Three basic findings in patients with pustular
SKALP that is already in a partly denatured state. There- psoriasis support this concept: (1) the presence of latent
fore, a possible explanation for this observation is that a (complexed) SKALP in scale extracts, (2) the presence of
certain amount of SKALP is denatured by boiling the free elastase in 25% of the patients, and (3) low levels of
scale extracts. Alternatively, it could be due to the pres- SKALP in pustular psoriasis, 
ence of small amounts of other heat-labile proteinase in­
hibitors.
In biopsies from pustular psoriasis patients from a re- ity in the scale extracts could be explained by the method-
from the entire surface of
The fact that in the pustular psoriasis group not all pa­
tients showed significant amounts of latent SKALP activ-
gion with pustules, SKALP levels as measured using the ology. We used scales obtai
functional assay were significantly decreased compared the trunk or the hand. Since pustule formation is a local-
with plaque psoriasis. This discrepancy is not related to ized phenomenon, the information we obtain from our
differences in the body region, since in both scales and measurements is an average in which the information con-
biopsies from patients with generalized pustular psoriasis ceming the local situation of a pustule is ‘diluted’. Fur-
(obtained from trunk and extremities) and in samples fhermore, we showed with immunohistology that SKALP
from pustulosis palmoplantaris patients (all obtained from expression can vary between individual patients.
the palms) low amounts of free and total SKALP were Irrespective of the mechanism for SKALP deficiency,
found. In scales from five patients with pustular psoriasis which could have a genetic basis or be an extracellular
no free SKALP activity could be measured. In these cases mechanism, it is clear that it would lead to excessive pro-
free elastase activity was found, indicating that all avail- teolysis of structural epidermal proteins. The data from
able SKALP was saturated with elastase. Latent SKALP the present study provide evidence that control of elastase
in these scales was liberated by heat inactivation of the activity is a pathogenic factor in pustular forms of psoria-
scale extracts. This phenomenon has been found previ- sis. We would hypothesize that the use of (preferably top-
ously in urine from patients with severe erythrodermic ical) low molecular weight drugs with anti-elastase activity
psoriasis [17]. Apart from these five patients in whom all could be a new therapeutic modality in pustular forms of 
SKALP activity was in a latent form, we found that a con­
siderable number of the pustular psoriasis patients had 
SKALP partially in a latent form. These findings support
the notion that SKALP has a biological function in vivo to References
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